Bioinformatics in new generation flavivirus vaccines

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Osterhaus, Albert D M E ^a   Koraka, Penelope ^a   Martina, Byron E E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; FLAVIVIRUS VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS VACCINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; B LYMPHOCYTE; CODON; CROSS REACTION; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; FLAVIVIRUS INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INTERNET; JAPANESE ENCEPHALITIS VIRUS; LONGEVITY; MORBIDITY; MORTALITY; NONHUMAN; OPEN READING FRAME; POLYADENYLATION; PROCESS OPTIMIZATION; REVIEW; T LYMPHOCYTE; TICK BORNE ENCEPHALITIS FLAVIVIRUS; TRANSCRIPTION REGULATION; YELLOW FEVER FLAVIVIRUS; ANIMAL; ARTICLE; BIOLOGY; FLAVIVIRUS; IMMUNOLOGY; METHODOLOGY;

ARTHROPODA; FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS; TICK-BORNE ENCEPHALITIS VIRUS; YELLOW FEVER VIRUS;

ANIMALS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HUMANS; VIRAL VACCINES;

EID: 77952477221     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/864029     Document Type: Review

References (161)

1. Gaunt M. W., Sall A. A., de Lamballerie X., Falconar A. K. I., Dzhivanian T. I., Gould E. A., Phylogenetic relationships of flaviviruses correlate with their epidemiology, disease association and biogeography Journal of General Virology 2001 82, part 8 1867 1876
2. Kuno G., Chang G.-J. J., Tsuchiya K. R., Karabatsos N., Cropp C. B., Phylogeny of the genus Flavivirus Journal of Virology 1998 72 1 73 83
3. Oya A., Kurane I., Japanese encephalitis for a reference to international travelers Journal of Travel Medicine 2007 14 4 259 268
4. Blitvich B. J., Transmission dynamics and changing epidemiology of West Nile virus Animal Health Research Reviews 2008 9 1 71 86
5. Halstead S. B., Dengue The Lancet 2007 370 9599 1644 1652
6. Gould E., Solomon T., Pathogenic flaviviruses The Lancet 2008 371 9611 500 509
7. Lindenbach B. D., Rice C. M., Molecular biology of flaviviruses Advances in Virus Research 2003 59 23 61
8. Crill W. D., Chang G.-J. J., Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes Journal of Virology 2004 78 24 13975 13986
9. Roehrig J. T., Bolin R. A., Kelly R. G., Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica Virology 1998 246 2 317 328
10. Diamond M. S., Pierson T. C., Fremont D. H., The structural immunology of antibody protection against West Nile virus Immunological Reviews 2008 225 1 212 225
11. Oliphant T., Nybakken G. E., Engle M., Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein Journal of Virology 2006 80 24 12149 12159
12. Volk D. E., Beasley D. W. C., Kallick D. A., Holbrook M. R., Barrett A. D. T., Gorenstein D. G., Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus The Journal of Biological Chemistry 2004 279 37 38755 38761
13. Beasley D. W. C., Barrett A. D. T., Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein Journal of Virology 2002 76 24 13097 13100
14. Pierson T. C., Xu Q., Nelson S., The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection Cell Host and Microbe 2007 1 2 135 145
15. Oliphant T., Engle M., Nybakken G. E., Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus Nature Medicine 2005 11 5 522 530
16. Diamond M. S., Sitati E. M., Friend L. D., Higgs S., Shrestha B., Engle M., A critical role for induced IgM in the protection against West Nile virus infection Journal of Experimental Medicine 2003 198 12 1853 1862
17. + T cells in control of West Nile virus infection Journal of Virology 2004 78 15 8312 8321
18. Brien J. D., Uhrlaub J. L., Nikolich-Zugich J., West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection Journal of Immunology 2008 181 12 8568 8575
19. + T cells Journal of Immunology 2009 182 8 4865 4873
20. Gubler D. J., Dengue and dengue hemorrhagic fever Clinical Microbiology Reviews 1998 11 3 480 496
21. Kouri G. P., Guzman M. G., Bravo J. R., Triana C., Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981 Bulletin of the World Health Organization 1989 67 4 375 380
22. Ooi E. E., Goh K. T., Gubler D. J., Dengue prevention and 35 years of vector control in Singapore Emerging Infectious Diseases 2006 12 6 887 893
23. Theiler M., Smith H. H., The use of yellow fever virus modified by in vitro cultivation for human immunization The Journal of Experimental Medicine 1937 65 6 787 800
24. Brusic V., August J. T., Petrovsky N., Information technologies for vaccine research Expert Review of Vaccines 2005 4 3 407 417
25. Eckels K. H., Putnak R., Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines Advances in Virus Research 2003 61 395 418
26. Appaiahgari M. B., Vrati S., Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells Vaccine 2004 22 27-28 3669 3675
27. Sugawara K., Nishiyama K., Ishikawa Y., Development of vero cell-derived inactivated Japanese encephalitis vaccine Biologicals 2002 30 4 303 314
28. Wilder-Smith A., Freedman D. O., Japanese encephalitis: is there a need for a novel vaccine? Expert Review of Vaccines 2009 8 8 969 972
29. Plesner A. M., Allergic reactions to Japanese encephalitis vaccine Immunology and Allergy Clinics of North America 2003 23 4 665 697
30. de Swart R. L., van den Hoogen B. G., Kuiken T., Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection Vaccine 2007 25 51 8518 8528
31. De Swart R. L., Kuiken T., Timmerman H. H., Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection Journal of Virology 2002 76 22 11561 11569
32. Martina B. E., Koraka P., van den Doel P., van Amerongen G., Rimmelzwaan G. F., Osterhaus A. D. M. E., Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus Vaccine 2008 26 2 153 157
33. Chu J.-H. J., Chiang C.-C. S., Ng M.-L., Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection Journal of Immunology 2007 178 5 2699 2705
34. Zhang W., Du X., Zhao G., Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination Vaccine 2009 27 36 4938 4946
35. Stahl-Hennig C., Eisenbltter M., Jasny E., Synthetic double-stranded RNAs are adjuvants for the induction of t helper 1 and humoral immune responses to human papillomavirus in rhesus macaques PLoS Pathogens 2009 5 4
36. Lau Y. F., Tang L.-H., Ooi E.-E., A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic Vaccine 2009 27 9 1354 1364
37. Gupta K., Cooper C., A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases Drugs in R and D 2008 9 3 137 145
38. Higgins D., Marshall J. D., Traquina P., Van Nest G., Livingston B. D., Immunostimulatory DNA as a vaccine adjuvant Expert Review of Vaccines 2007 6 5 747 759
39. Park B. S., Song D. H., Kim H. M., Choi B. S., Lee H., Lee J. O., The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex Nature 2009 458 7242 1191 1195
40. Leonard J. N., Bell J. K., Segal D. M., Predicting Toll-like receptor structures and characterizing ligand binding Methods in Molecular Biology 2009 517 55 67
41. Monie T. P., Gay N. J., Gangloff M., Bioinformatic analysis of Toll-like receptor sequences and structures Methods in Molecular Biology 2009 517 69 79
42. McDonald W. F., Huleatt J. W., Foellmer H. G., A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity Journal of Infectious Diseases 2007 195 11 1607 1617
43. Seligman S. J., Gould E. A., Live flavivirus vaccines: reasons for caution The Lancet 2004 363 9426 2073 2075
44. Koraka P., Benton S., van Amerongen G., Stittelaar K. J., Osterhaus A. D. M. E., Efficacy of a live attenuated tetravalent candidate dengue vaccine in naive and previously infected cynomolgus macaques Vaccine 2007 25 29 5409 5416
45. Sun W., Nisalak A., Gettayacamin M., Protection of rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination Journal of Infectious Diseases 2006 193 12 1658 1665
46. Sun W., Cunningham D., Wasserman S. S., Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults Human Vaccines 2009 5 1 33 40
47. Simasathien S., Thomas S. J., Watanaveeradej V., Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children American Journal of Tropical Medicine and Hygiene 2008 78 3 426 433
48. Kitchener S., Nissen M., Nasveld P., Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults Vaccine 2006 24 9 1238 1241
49. Alvarez D. E., De Lella Ezcurra A. L., Fucito S., Gamarnik A. V., Role of RNA structures present at the 3 ′ UTR of dengue virus on translation, RNA synthesis, and viral replication Virology 2005 339 2 200 212
50. Proutski V., Gaunt M. W., Gould E. A., Holmes E. C., Secondary structure of the 3 ′-untranslated region of yellow fever virus: implications for virulence, attenuation and vaccine development Journal of General Virology 1997 78, part 7 1543 1549
51. Proutski V., Gould E. A., Holmes E. C., Secondary structure of the 3 ′ untranslated region of flaviviruses: similarities and differences Nucleic Acids Research 1997 25 6 1194 1202
52. Proutski V., Gritsun T. S., Gould E. A., Holmes E. C., Biological consequences of deletions within the 3 ′-untranslated region of flaviviruses may be due to rearrangements of RNA secondary structure Virus Research 1999 64 2 107 123
53. Blaney J. E. Jr., Johnson D. H., Manipon G. G., Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells Virology 2002 300 1 125 139
54. Durbin A. P., Karron R. A., Sun W., Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3 ′-untranslated region American Journal of Tropical Medicine and Hygiene 2001 65 5 405 413
55. Whitehead S. S., Falgout B., Hanley K. A., Blaney J. E. Jr., Markoff L., Murphy B. R., A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3 ′ untranslated region is highly attenuated and immunogenic in monkeys Journal of Virology 2003 77 2 1653 1657
56. Blaney J. E. Jr., Hanson C. T., Firestone C. Y., Hanley K. A., Murphy B. R., Whitehead S. S., Genetically modified, live attenuated dengue virus type 3 vaccine candidates American Journal of Tropical Medicine and Hygiene 2004 71 6 811 821
57. Blaney J. E. Jr., Hanson C. T., Hanley K. A., Murphy B. R., Whitehead S. S., Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2 BMC Infectious Diseases 2004 4 4, article 39
58. Blaney J. E. Jr., Sathe N. S., Goddard L., Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3 ′ untranslated region (3 ′-UTR) or by exchange of the DENV-3 3 ′-UTR with that of DENV-4 Vaccine 2008 26 6 817 828
59. Hahn C. S., Dalrymple J. M., Strauss J. H., Rice C. M., Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it Proceedings of the National Academy of Sciences of the United States of America 1987 84 7 2019 2023
60. Xu Z.-L., Mizuguchi H., Ishii-Watabe A., Uchida E., Mayumi T., Hayakawa T., Optimization of transcriptional regulatory elements for constructing plasmid vectors Gene 2001 272 1-2 149 156
61. Beck C., Uramoto H., Boren J., Akyurek L. M., Tissue-specific targeting for cardiovascular gene transfer. Potential vectors and future challenges Current Gene Therapy 2004 4 4 457 467
62. Brooks A. R., Harkins R. N., Wang P., Qian H. S., Liu P., Rubanyi G. M., Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle Journal of Gene Medicine 2004 6 4 395 404
63. Qin L., Ding Y., Pahud D. R., Chang E., Imperiale M. J., Bromberg J. S., Promoter attenuation in gene therapy: interferon-and tumor necrosis factor-inhibit transgene expression Human Gene Therapy 1997 8 17 2019 2029
64. Al-Dosari M., Zhang G., Knapp J. E., Liu D., Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver Biochemical and Biophysical Research Communications 2006 339 2 673 678
65. Takeshita F., Takase K., Tozuka M., Muscle creatine kinase/SV40 hybrid promoter for muscle-targeted long-term transgene expression International Journal of Molecular Medicine 2007 19 2 309 315
66. Mori-Uchino M., Takeuchi T., Murakami I., Enhanced transgene expression in the mouse skeletal muscle infected by the adeno-associated viral vector with the human elongation factor 1 promoter and a human chromatin insulator Journal of Gene Medicine 2009 11 7 598 604
67. Hong S., Hwang D. Y., Yoon S., Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells Molecular Therapy 2007 15 9 1630 1639
68. Vanniasinkam T., Reddy S. T., Ertl H. C. J., DNA immunization using a non-viral promoter Virology 2006 344 2 412 420
69. Song J.-S., Activity of the human telomerase catalytic subunit (hTERT) gene promoter could be increased by the SV40 enhancer Bioscience, Biotechnology and Biochemistry 2004 68 8 1634 1639
70. Yago M., Ohki R., Hatakeyama S., Fujita T., Ishikawa F., Variant forms of upstream stimulatory factors (USFs) control the promoter activity of hTERT, the human gene encoding the catalytic subunit of telomerase FEBS Letters 2002 520 13 40 46
71. Horikawa I., Cable P. L., Afshari C., Barrett J. C., Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene Cancer Research 1999 59 4 826 830 (Pubitemid 29086735)
72. Ashok M. S., Rangarajan P. N., Protective efficacy of a plasmid DNA encoding Japanese encephalitis virus envelope protein fused to tissue plasminogen activator signal sequences: studies in a murine intracerebral virus challenge model Vaccine 2002 20 11-12 1563 1570
73. Guo Z. S., Li Q., Bartlett D. L., Yang J. Y., Fang B., Gene transfer: the challenge of regulated gene expression Trends in Molecular Medicine 2008 14 9 410 418
74. Lee A. H., Suh Y. S., Sung J. H., Yang S. H., Sung Y. C., Comparison of various expression plasmids for the induction of immune response by DNA immunization Molecules and Cells 1997 7 4 495 501
75. Chapman B. S., Thayer R. M., Vincent K. A., Haigwood N. L., Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells Nucleic Acids Research 1991 19 14 3979 3986
76. Chinsangaram J., Beard C., Mason P. W., Zellner M. K., Ward G., Grubman M. J., Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins Journal of Virology 1998 72 5 4454 4457
77. Huang M. T. F., Gorman C. M., Intervening sequences increase efficiency of RNA 3 ′ processing and accumulation of cytoplasmic RNA Nucleic Acids Research 1990 18 4 937 947
78. Huang M. T. F., Gorman C. M., The simian virus 40 small-t intron, present in many common expression vectors, leads to aberrant splicing Molecular and Cellular Biology 1990 10 4 1805 1810
79. You L.-M., Luo J., Wang A.-P., A hybrid promoter-containing vector for direct cloning and enhanced expression of PCR-amplified ORFs in mammalian cells. Molecular Biology Reports. In press
80. Garg S., Oran A. E., Hon H., Jacob J., The hybrid cytomegalovirus enhancer/chicken-actin promoter along with woodchuck hepatitis virus posttranscriptional regulatory element enhances the protective efficacy of DNA vaccines Journal of Immunology 2004 173 1 550 558
81. Alexopoulou A. N., Couchman J. R., Whiteford J. R., The CMV early enhancer/chicken actin (CAG) promoter can be used to drive transgene expression during the differentiation of murine embryonic stem cells into vascular progenitors BMC Cell Biology 2008 9, article 2
82. Chang G.-J. J., Davis B. S., Hunt A. R., Holmes D. A., Kuno G., Flavivirus DNA vaccines: current status and potential Annals of the New York Academy of Sciences 2001 951 272 285
83. Jathoul A. P., Holley J. L., Garmory H. S., Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters Vaccine 2004 22 29-30 3942 3946
84. Santos K., Duke C. M. P., Rodriguez-Colon S. M., Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag Vaccine 2007 25 9 1634 1646
85. Wang S., Farfan-Arribas D. J., Shen S., Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine Vaccine 2006 24 21 4531 4540
86. Zhao J., Hyman L., Moore C., Formation of mRNA 3 ′ ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis Microbiology and Molecular Biology Reviews 1999 63 2 405 445
87. Gilmartin G. M., Nevins J. R., An ordered pathway of assembly of components required for polyadenylation site recognition and processing Genes and Development 1989 3 12B 2180 2190
88. Montell C., Fisher E. F., Caruthers M. H., Berk A. J., Inhibition of RNA cleavage but not polyadenylation by a point mutation in mRNA 3 ′ consensus sequence AAUAAA Nature 1983 305 5935 600 605
89. Sheets M. D., Ogg S. C., Wickens M. P., Point mutations of AAUAAA and the poly (A) addition site: effects on the accuracy and efficiency of cleavage and polyadenylation in vitro Nucleic Acids Research 1990 18 19 5799 5805
90. Hans H., Alwine J. C., Functionally significant secondary structure of the simian virus 40 late polyadenylation signal Molecular and Cellular Biology 2000 20 8 2926 2932
91. Gimmi E. R., Reff M. E., Deckman I. C., Alterations in the pre-mRNA topology of the bovine growth hormone polyadenylation region decrease poly(A) site efficiency Nucleic Acids Research 1989 17 17 6983 6998
92. Roth C. M., Sundaram S., Engineering synthetic vectors for improved DNA delivery: insights from intracellular pathways Annual Review of Biomedical Engineering 2004 6 397 426
93. Schirmbeck R., Konig-Merediz S. A., Riedl P., Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide Journal of Molecular Medicine 2001 79 5-6 343 350
94. 2+-sensitive cytosolic nucleases prevent efficient delivery to the nucleus of injected plasmids Journal of Gene Medicine 2001 3 2 153 164
95. Azzoni A. R., Ribeiro S. C., Monteiro G. A., Prazeres D. M. F., The impact of polyadenylation signals on plasmid nuclease-resistance and transgene expression Journal of Gene Medicine 2007 9 5 392 402
96. Ribiero S. C., Monteiro G. A., Prazeres D. M., The role of polyadenylation signal secondary structures on the resistance of plasmid vectors to nucleases Journal of Gene Medicine 2004 6 5 565 573
97. Ikemura T., Correlation between the abundance of Escherichia coli transfer RNAs and the occurrence of the respective codons in its protein genes Journal of Molecular Biology 1981 146 1 1 21
98. Zhou J., Liu W. J., Peng S. W., Sun X. Y., Frazer I., Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability Journal of Virology 1999 73 6 4972 4982
99. Ikemura T., Codon usage and tRNA content in unicellular and multicellular organisms Molecular Biology and Evolution 1985 2 1 13 34
100. Ikemura T., Correlation between the abundance of yeast transfer RNAs and the occurrence of the respective codons in protein genes. Differences in synonymous codon choice patterns of yeast and Escherichia coli with reference to the abundance of isoaccepting transfer RNAs Journal of Molecular Biology 1982 158 4 573 597
101. Grantham R., Gautier C., Gouy M., Jacobzone M., Mercier R., Codon catalog usage is a genome strategy modulated for gene expressivity Nucleic Acids Research 1981 9 1 r43 r74
102. Sharp P. M., Tuohy T. M., Mosurski K. R., Codon usage in yeast: cluster analysis clearly differentiates highly and lowly expressed genes Nucleic Acids Research 1986 14 13 5125 5143
103. Wang A., Ren L., Abenes G., Hai R., Genome sequence divergences and functional variations in human cytomegalovirus strains FEMS Immunology and Medical Microbiology 2009 55 1 23 33
104. Stenstrom C. M., Isaksson L. A., Influences on translation initiation and early elongation by the messenger RNA region flanking the initiation codon at the 3 ′ side Gene 2002 288 1-2 1 8
105. Looman A. C., Bodlaender J., Comstock L. J., Influence of the codon following the AUG initiation codon on the expression of a modified lacZ gene in Escherichia coli EMBO Journal 1987 6 8 2489 2492
106. Komar A. A., Lesnik T., Reiss C., Synonymous codon substitutions affect ribosome traffic and protein folding during in vitro translation FEBS Letters 1999 462 3 387 391
107. Sharp P. M., Li W. H., The codon adaptation indexa measure of directional synonymous codon usage bias, and its potential applications Nucleic Acids Research 1987 15 3 1281 1295
108. Deml L., Bojak A., Steck S., Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein Journal of Virology 2001 75 22 10991 11001
109. Uchijima M., Yoshida A., Nagata T., Koide Y., Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium Journal of Immunology 1998 161 10 5594 5599
110. Nagata T., Uchijima M., Yoshida A., Kawashima M., Koide Y., Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: analysis of plasmid DNA encoding a CTL epitope derived from microorganisms Biochemical and Biophysical Research Communications 1999 261 2 445 451
111. Cheung Y.-K., Cheng S. C.-S., Sin F. W.-Y., Xie Y., Plasmid encoding papillomavirus type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection Vaccine 2004 23 5 629 638
112. Frelin L., Ahlen G., Alheim M., Codon optimization and mRNA amplification effectively enhances the immunogenecity of the hepatitis C virus nonstructural 3/4A gene Gene Therapy 2004 11 6 522 533
113. Gao F., Li Y., Decker J. M., Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice AIDS Research and Human Retroviruses 2003 19 9 817 823
114. Ko H. J., Ko S. Y., Kim Y. J., Lee E. G., Cho S.-N., Kang C.-Y., Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B Infection and Immunity 2005 73 9 5666 5674
115. Kozak M., Regulation of translation via mRNA structure in prokaryotes and eukaryotes Gene 2005 361 1-2 13 37
116. Cavener D. R., Ray S. C., Eukaryotic start and stop translation sites Nucleic Acids Research 1991 19 12 3185 3192
117. Kutay U., Ahnert-Hilger G., Hartmann E., Wiedenmann B., Rapoport T. A., Transport route for synaptobrevin via a novel pathway of insertion into the endoplasmic reticulum membrane EMBO Journal 1995 14 2 217 223
118. Martoglio B., Dobberstein B., Signal sequences: more than just greasy peptides Trends in Cell Biology 1998 8 10 410 415
119. Zalucki Y. M., Beacham I. R., Jennings M. P., Biased codon usage in signal peptides: a role in protein export Trends in Microbiology 2009 17 4 146 150
120. Sakaguchi M., Tomiyoshi R., Kuroiwa T., Mihara K., Omura T., Functions of signal and signal-anchor sequences are determined by the balance between the hydrophobic segment and the N-terminal charge Proceedings of the National Academy of Sciences of the United States of America 1992 89 1 16 19
121. Sominskaya I., Alekseeva E., Skrastina D., Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene Molecular Immunology 2006 43 12 1941 1952
122. Li Z., Howard A., Kelley C., Delogu G., Collins F., Morris S., Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences Infection and Immunity 1999 67 9 4780 4786
123. Luo M., Tao P., Li J., Zhou S., Guo D., Pan Z., Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice Journal of Virological Methods 2008 154 1-2 121 127
124. Jiang C., Magee D. M., Ivey F. D., Cox R. A., Role of signal sequence in vaccine-induced protection against experimental coccidioidomycosis Infection and Immunity 2002 70 7 3539 3545
125. Putnak R., Porter K., Schmaljohn C., DNA vaccines for flaviviruses Advances in Virus Research 2003 61 445 468
126. Wu C. J., Li T. L., Huang H. W., Tao M. H., Chan Y. L., Development of an effective Japanese encephalitis virus-specific DNA vaccine Microbes and Infection 2006 8 11 2578 2586
127. Chang G.-J. J., Hunt A. R., Davis B., A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice Journal of Virology 2000 74 9 4244 4252
128. Konishi E., Yamaoka M., Khin-Sane-Win, Kurane I., Mason P. W., Induction of protective immunity against japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes Journal of Virology 1998 72 6 4925 4930
129. Davis B. S., Chang G.-J. J., Cropp B., West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays Journal of Virology 2001 75 9 4040 4047
130. Martin J. E., Pierson T. C., Hubka S., A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial Journal of Infectious Diseases 2007 196 12 1732 1740
131. Kaur R., Sachdeva G., Vrati S., Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membrane-anchored and secretory envelope protein Journal of Infectious Diseases 2002 185 1 1 12
132. Raviprakash K., Kochel T. J., Ewing D., Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein Vaccine 2000 18 22 2426 2434
133. Raviprakash K., Porter K. R., Needle-free injection of DNA vaccines: a brief overview and methodology Methods in Molecular Medicine 2006 127 83 89
134. Raviprakash K., Marques E., Ewing D., Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF Virology 2001 290 1 74 82
135. Bharati K., Appaiahgari M. B., Vrati S., Effect of cytokine-encoding plasmid delivery on immune response to Japanese encephalitis virus DNA vaccine in mice Microbiology and Immunology 2005 49 4 349 353
136. Lu Y., Raviprakash K., Leao I. C., Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies Vaccine 2003 21 17-18 2187 2198
137. Isaji K., Kawase A., Matono M., Guan X., Nishikawa M., Takakura Y., Enhanced CTL response by controlled intracellular trafficking of antigen in dendritic cells following DNA vaccination Journal of Controlled Release 2009 135 3 227 233
138. Kim S. J., Lee C., Lee S. Y., Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES Gene Therapy 2003 10 15 1268 1273
139. Chang D. C., Liu W. J., Anraku I., Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus Nature Biotechnology 2008 26 5 571 577
140. Nam J. H., Bang H. S., Cho H. W., Chung Y. H., Different contribution of co-stimulatory molecules B7.1 and B7.2 to the immune response to recombinant modified vaccinia virus ankara vaccine expressing prM/E proteins of Japanese encephalitis virus and two hepatitis B virus vaccines Acta Virologica 2007 51 2 125 130
141. Men R., Wyatt L., Tokimatsu I., Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge Vaccine 2000 18 27 3113 3122
142. + cytotoxic T lymphocytes in mice Virology 1997 227 2 353 360 (Pubitemid 27241028)
143. Seino K. K., Long M. T., Gibbs E. P. J., Comparative efficacies of three commercially available vaccines against West Nile virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model Clinical and Vaccine Immunology 2007 14 11 1465 1471
144. Raviprakash K., Wang D., Ewing D., A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus Journal of Virology 2008 82 14 6927 6934
145. Khanam S., Khanna N., Swaminathan S., Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors Vaccine 2006 24 42-43 6513 6525
146. Appaiahgari M. B., Saini M., Rauthan M., Jyoti, Vrati S., Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis Microbes and Infection 2006 8 1 92 104
147. Despres P., Combredet C., Frenkiel M.-P., Lorin C., Brahic M., Tangy F., Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis Journal of Infectious Diseases 2005 191 2 207 214
148. White L. J., Parsons M. M., Whitmore A. C., Williams B. M., De Silva A., Johnston R. E., An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice Journal of Virology 2007 81 19 10329 10339
149. Fleeton M. N., Liljestrm P., Sheahan B. J., Atkins G. J., Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine Journal of General Virology 2000 81, part 3 749 758
150. Colombage G., Hall R., Pavy M., Lobigs M., DNA-based and alphavirus-vectored immunisation with PrM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus Virology 1998 250 1 151 163
151. Iyer A. V., Pahar B., Boudreaux M. J., Recombinant vesicular stomatitis virus-based West Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent West Nile virus strain LSU-AR01 Vaccine 2009 27 6 893 903
152. Stittelaar K. J., Kuiken T., de Swart R. L., Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques Vaccine 2001 19 27 3700 3709
153. Swenson D. L., Wang D., Luo M., Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections Clinical and Vaccine Immunology 2008 15 3 460 467
154. Schepp-Berglind J., Luo M., Wang D., Complex adenovirus-mediated expression of West Nile Virus C, preM, E, and NS1 proteins induces both humoral and cellular immune responses Clinical and Vaccine Immunology 2007 14 9 1117 1126
155. Nam J. H., Chae S. L., Cho H. W., Immunogenicity of a recombinant MVA and a DNA vaccine for Japanese encephalitis virus in swine Microbiology and Immunology 2002 46 1 23 28
156. Wang B., Li J., Fu F. H., Construction and analysis of compact muscle-specific promoters for AAV vectors Gene Therapy 2008 15 22 1489 1499
157. Hall R. A., Khromykh A. A., ChimeriVax-West Nile vaccine Current Opinion in Molecular Therapeutics 2007 9 5 498 504
158. Dauphin G., Zientara S., West Nile virus: recent trends in diagnosis and vaccine development Vaccine 2007 25 30 5563 5576
159. Beasley D. W. C., Li L., Suderman M. T., Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine Vaccine 2004 22 27-28 3722 3726
160. McGee C. E., Lewis M. G., Claire M. S., Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates Journal of Infectious Diseases 2008 197 5 693 697
161. Guirakhoo F., Pugachev K., Arroyo J., Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates Virology 2002 298 1 146 159